NASDAQ:GILD - Gilead Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$67.63 -0.39 (-0.57 %)
(As of 05/22/2018 02:17 AM ET)
Previous Close$68.02
Today's Range$67.25 - $68.57
52-Week Range$63.76 - $89.54
Volume5.99 million shs
Average Volume8.16 million shs
Market Capitalization$88.44 billion
P/E Ratio7.90
Dividend Yield3.37%

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.

Receive GILD News and Ratings via Email

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic


Debt-to-Equity Ratio1.32
Current Ratio2.84
Quick Ratio2.75


Trailing P/E Ratio7.90
Forward P/E Ratio11.76
P/E Growth-5.91

Sales & Book Value

Annual Sales$26.11 billion
Price / Sales3.37
Cash Flow$9.5658 per share
Price / Cash7.07
Book Value$15.69 per share
Price / Book4.31


EPS (Most Recent Fiscal Year)$8.56
Net Income$4.63 billion
Net Margins14.03%
Return on Equity45.49%
Return on Assets15.63%


Outstanding Shares1,300,260,000

Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Tuesday, May 1st. Stockholders of record on Friday, June 15th will be paid a dividend of $0.57 per share on Thursday, June 28th. This represents a $2.28 annualized dividend and a dividend yield of 3.37%. The ex-dividend date of this dividend is Thursday, June 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences (NASDAQ:GILD) announced its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.67 by $0.19. The biopharmaceutical company had revenue of $5.09 billion for the quarter, compared to analysts' expectations of $5.40 billion. Gilead Sciences had a return on equity of 45.49% and a net margin of 14.03%. The company's revenue was down 21.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.23 EPS. View Gilead Sciences' Earnings History.

When is Gilead Sciences' next earnings date?

Gilead Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Gilead Sciences.

What price target have analysts set for GILD?

23 brokers have issued 12 month price objectives for Gilead Sciences' stock. Their predictions range from $72.00 to $105.00. On average, they expect Gilead Sciences' share price to reach $88.1458 in the next twelve months. View Analyst Ratings for Gilead Sciences.

What are Wall Street analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:
  • 1. According to Zacks Investment Research, "Gilead’s first-quarter results were disappointing with both earnings and sales missing estimates as the magnitude of the decline in HCV sales was wider-than-expected due to lower patient starts and increasing competition. Nevertheless, Gilead is now banking on its HIV franchise and newer avenues like the CAR-T therapy to drive growth. The HIV franchise maintains momentum driven by the rapid adoption of Descovy-based regimens. The FDA approval of Biktarvy has further widened the portfolio. The CHMP has also adopted a positive opinion on the regimen and a tentative approval is expected in the third-quarter. The initial uptake of Yescarta is encouraging. Meanwhile, Gilead is intending to foray into the NASH market with selonsertib and filgotinib. Both the candidates are being evaluated in late stage studies and a tentative approval will diversify Gilead’s portfolio.Shares have performed better than the industry in the last twelve months." (5/7/2018)
  • 2. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
  • 3. Leerink Swann analysts commented, "RARE’s 4Q report this afternoon was relatively in line with expectations. Incremental clinical updates for burosumab in young children and in adults with osteomalacia (bone softening) in the report further support the drug’s utility in both populations. The year ahead is shaping up to be catalyst-rich for RARE, with data from two gene therapy programs, the Phase 3 of trihep in Glut1 DS, and a decision on trihep registration plans in FAOD expected over the coming months. Although we continue to expect a slow rollout of burosumab (PDUFA date 4/17/18) and Mepsevii, we see opportunity for further upside in shares over the course of 2018. Maintain OW." (2/22/2018)
  • 4. BMO Capital Markets analysts commented, "Early biopotency signals from a single patient dosed with ABO-101 (for Sanfilippo B), demonstrate targeted reduction on toxic sugars." (2/7/2018)
  • 5. Maxim Group analysts commented, "We returned from Beijing, China and listened as Tim Moore, EVP of Technical Operations and the CEO of Fosun Kite Biotechnology co. (Richard Wang) presented manufacturing plans for the launch of Yescarta, and the opportunity in China (see the slides in the pages that follow). Suffice to say, we were impressed and left clear with the notion that Gilead (and Kite) can overcome manufacturing challenges to commercialize in the U.S. and globally, especially China, this new innovative therapy. As a result, we are upgrading Gilead to Buy, from Hold and establishing a $94 price target." (11/30/2017)

Who are some of Gilead Sciences' key competitors?

Who are Gilead Sciences' key executives?

Gilead Sciences' management team includes the folowing people:
  • Dr. John F. Milligan, CEO, Pres & Director (Age 57)
  • Ms. Robin L. Washington, CFO & Exec. VP (Age 55)
  • Dr. Norbert W. Bischofberger, Exec. VP of R&D and Chief Scientific Officer (Age 62)
  • Mr. Gregg H. Alton, Exec. VP of Corp. & Medical Affairs and Interim Head of International Commercial Operations (Age 52)
  • Mr. Kevin B. Young, Advisory (Age 60)

Has Gilead Sciences been receiving favorable news coverage?

Media stories about GILD stock have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Gilead Sciences earned a daily sentiment score of 0.17 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 47.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Gilead Sciences' major shareholders?

Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.07%), Northern Trust Corp (1.27%), Franklin Resources Inc. (1.03%), Amundi Pioneer Asset Management Inc. (0.65%), Boston Partners (0.62%) and OppenheimerFunds Inc. (0.54%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Which major investors are selling Gilead Sciences stock?

GILD stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., CI Investments Inc., Swiss National Bank, Amundi Pioneer Asset Management Inc., Envestnet Asset Management Inc., Sentry Investments Corp., Franklin Resources Inc. and Legal & General Group Plc. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Insider Buying and Selling for Gilead Sciences.

Which major investors are buying Gilead Sciences stock?

GILD stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Farallon Capital Management LLC, State Treasurer State of Michigan, BlackRock Inc., PointState Capital LP, Diamond Hill Capital Management Inc., Millennium Management LLC and Mackay Shields LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy shares of Gilead Sciences?

Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Gilead Sciences' stock price today?

One share of GILD stock can currently be purchased for approximately $67.63.

How big of a company is Gilead Sciences?

Gilead Sciences has a market capitalization of $88.44 billion and generates $26.11 billion in revenue each year. The biopharmaceutical company earns $4.63 billion in net income (profit) each year or $8.56 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.

How can I contact Gilead Sciences?

Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]

MarketBeat Community Rating for Gilead Sciences (GILD)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  1,698 (Vote Outperform)
Underperform Votes:  649 (Vote Underperform)
Total Votes:  2,347
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Gilead Sciences (NASDAQ:GILD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
23 Wall Street analysts have issued ratings and price targets for Gilead Sciences in the last 12 months. Their average twelve-month price target is $88.1458, suggesting that the stock has a possible upside of 30.34%. The high price target for GILD is $105.00 and the low price target for GILD is $72.00. There are currently 9 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.612.642.612.57
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $88.1458$88.7033$86.99$84.5987
Price Target Upside: 30.34% upside17.53% upside9.67% upside14.68% upside

Gilead Sciences (NASDAQ:GILD) Consensus Price Target History

Price Target History for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2018Needham & Company LLCReiterated RatingHoldHighView Rating Details
5/2/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$85.00 ➝ $81.00LowView Rating Details
5/2/2018BarclaysLower Price TargetOverweight ➝ Buy$95.00 ➝ $90.00HighView Rating Details
5/2/2018Leerink SwannSet Price TargetMarket Perform$80.00 ➝ $72.00HighView Rating Details
4/17/2018Credit Suisse GroupSet Price TargetHold$80.00LowView Rating Details
2/23/2018Royal Bank of CanadaReiterated RatingBuy$94.00LowView Rating Details
2/12/2018MizuhoReiterated RatingBuy ➝ Buy$83.00 ➝ $95.00LowView Rating Details
2/8/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Market Perform$86.00 ➝ $88.00HighView Rating Details
2/8/2018CitigroupReiterated RatingBuy ➝ Buy$103.00 ➝ $105.00HighView Rating Details
2/7/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$82.00 ➝ $87.00MediumView Rating Details
2/6/2018Maxim GroupSet Price TargetBuy$94.00HighView Rating Details
1/26/2018Jefferies GroupUpgradeHold ➝ Buy$81.19 ➝ $93.00HighView Rating Details
1/16/2018Wells FargoUpgradeMarket Perform ➝ Outperform$79.02 ➝ $96.00LowView Rating Details
12/21/2017OppenheimerReiterated RatingHoldMediumView Rating Details
11/13/2017ArgusDowngradeBuy ➝ Hold$73.25 ➝ $73.77N/AView Rating Details
10/25/2017JPMorgan ChaseSet Price TargetBuy$85.00N/AView Rating Details
10/19/2017William BlairReiterated RatingBuyN/AView Rating Details
10/19/2017Berenberg BankSet Price TargetBuy$96.00N/AView Rating Details
10/5/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformN/AView Rating Details
8/31/2017CowenReiterated RatingOutperform$90.00MediumView Rating Details
8/31/2017Deutsche BankReiterated RatingBuy$81.00MediumView Rating Details
8/29/2017Robert W. BairdReiterated RatingOutperform$87.00LowView Rating Details
7/26/2017Redburn PartnersInitiated CoverageBuyMediumView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
3/13/2017Goldman SachsReiterated RatingNeutral$70.00 ➝ $68.00LowView Rating Details
3/9/2017UBSReiterated RatingNeutral ➝ Neutral$118.00 ➝ $72.00N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
(Data available from 5/22/2016 forward)


Gilead Sciences (NASDAQ:GILD) Earnings History and Estimates Chart

Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Earnings Estimates

2018 EPS Consensus Estimate: $5.99
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$1.55$1.79$1.67
Q2 20183$1.35$1.46$1.40
Q3 20183$1.38$1.66$1.48
Q4 20183$1.31$1.66$1.43

Gilead Sciences (NASDAQ GILD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2018$1.55N/AView Earnings Details
5/1/2018Q1 2018$1.67$1.48$5.4042 billion$5.0880 billionViewListenView Earnings Details
2/6/2018Q4 2017$1.67$1.78$5.7118 billion$5.9490 billionViewListenView Earnings Details
10/26/2017Q3 2017$2.13$2.27$6.3970 billion$6.5120 billionViewN/AView Earnings Details
7/26/2017Q2 2017$2.11$2.56$6.3503 billion$7.1410 billionViewN/AView Earnings Details
5/2/2017Q1 2017$2.18$2.20$6.6604 billion$6.5050 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.2240 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.3140 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$4.9990 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.7828 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.5687 billion$2.5316 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.5880 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
7/26/2011Q2 2011$0.48$0.47ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
10/19/2010Q3 2010$0.42$0.43ViewN/AView Earnings Details
7/20/2010Q2 2010$0.41$0.40ViewN/AView Earnings Details
4/20/2010Q1 2010$0.46$0.47ViewN/AView Earnings Details
1/26/2010Q4 2009$0.41$0.45ViewN/AView Earnings Details
10/20/2009Q3 2009$0.35$0.37ViewN/AView Earnings Details
7/21/2009Q2 2009$0.31$0.33ViewN/AView Earnings Details
4/21/2009Q1 2009$0.30$0.32ViewN/AView Earnings Details
1/27/2009Q4 2008$0.28$0.30ViewN/AView Earnings Details
10/16/2008Q3 2008$0.25$0.26ViewN/AView Earnings Details
7/17/2008Q2 2008$0.25$0.23ViewN/AView Earnings Details
4/16/2008Q1 2008$0.24$0.26ViewN/AView Earnings Details
1/23/2008Q4 2007$0.21$0.21ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Gilead Sciences (NASDAQ:GILD) Dividend Information

Gilead Sciences pays an annual dividend of $2.28 per share, with a dividend yield of 3.37%. GILD's next quarterly dividend payment will be made on Thursday, June 28. Gilead Sciences pays out 26.64% of its earnings out as a dividend.
Next Dividend:6/28/2018
Annual Dividend:$2.28
Dividend Yield:3.37%
Payout Ratio(s):26.64% (Trailing 12 Months of Earnings)
39.65% (Based on This Year's Estimates)
36.66% (Based on Next Year's Estimates)
23.83% (Based on Cash Flow)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Gilead Sciences (NASDAQ GILD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.16%
Institutional Ownership Percentage: 77.72%
Insider Trading History for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ GILD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/4/2018John Francis CoganDirectorSell5,836$65.09$379,865.2458,455View SEC Filing  
5/1/2018John C MartinDirectorSell50,000$72.19$3,609,500.003,067,762View SEC Filing  
4/27/2018John Francis CoganDirectorSell5,833$73.91$431,117.0358,452View SEC Filing  
4/20/2018John Francis CoganDirectorSell5,833$73.74$430,125.4258,452View SEC Filing  
4/13/2018John Francis CoganDirectorSell5,833$75.56$440,741.4858,452View SEC Filing  
4/6/2018John Francis CoganDirectorSell5,833$74.47$434,383.5158,452View SEC Filing  
4/2/2018John C MartinDirectorSell50,000$73.14$3,657,000.003,067,762View SEC Filing  
3/23/2018John Francis CoganDirectorSell5,833$75.02$437,591.6658,452View SEC Filing  
3/16/2018John Francis CoganDirectorSell5,833$80.09$467,164.9758,452View SEC Filing  
3/12/2018John Francis CoganDirectorSell5,833$80.93$472,064.69View SEC Filing  
3/1/2018Gregg H AltonEVPSell25,000$78.69$1,967,250.0069,426View SEC Filing  
3/1/2018John C MartinChairmanSell50,000$78.65$3,932,500.003,067,762View SEC Filing  
2/28/2018Robin L WashingtonCFOSell5,000$80.31$401,550.0023,749View SEC Filing  
2/20/2018Gregg H AltonEVPSell14,435$81.54$1,177,029.90View SEC Filing  
2/9/2018Gayle E WilsonDirectorSell60,000$77.92$4,675,200.00182,258View SEC Filing  
2/1/2018Gregg H AltonEVPSell25,000$83.51$2,087,750.0062,738View SEC Filing  
2/1/2018John C MartinChairmanSell50,000$83.56$4,178,000.003,046,766View SEC Filing  
1/16/2018James R MeyersEVPSell100,000$80.24$8,024,000.00102,715View SEC Filing  
1/11/2018Gregg H AltonEVPSell30,000$79.00$2,370,000.0057,114View SEC Filing  
1/2/2018Gregg H AltonEVPSell15,000$73.87$1,108,050.0064,613View SEC Filing  
1/2/2018John C MartinInsiderSell50,000$73.62$3,681,000.003,046,766View SEC Filing  
12/1/2017Gregg H AltonEVPSell15,000$74.64$1,119,600.0070,988View SEC Filing  
12/1/2017John C MartinInsiderSell73,333$74.98$5,498,508.343,070,099View SEC Filing  
11/13/2017John F MilliganInsiderSell220,000$72.88$16,033,600.00View SEC Filing  
11/1/2017Gregg H AltonEVPSell15,000$74.82$1,122,300.0077,363View SEC Filing  
11/1/2017John C MartinInsiderSell73,333$75.13$5,509,508.293,070,099View SEC Filing  
10/2/2017Gregg H AltonEVPSell25,000$82.65$2,066,250.00View SEC Filing  
10/2/2017John C MartinInsiderSell73,333$82.56$6,054,372.48View SEC Filing  
9/7/2017Robin L WashingtonCFOSell51,820$85.00$4,404,700.0043,352View SEC Filing  
9/1/2017Gregg H AltonEVPSell25,000$83.05$2,076,250.00101,488View SEC Filing  
9/1/2017John C MartinInsiderSell73,333$83.11$6,094,705.632,996,766View SEC Filing  
8/31/2017James R MeyersEVPSell60,000$83.19$4,991,400.0062,715View SEC Filing  
8/30/2017Gregg H AltonEVPSell50,000$79.00$3,950,000.00113,237View SEC Filing  
8/1/2017Gregg H AltonEVPSell15,000$75.88$1,138,200.00106,113View SEC Filing  
8/1/2017John C MartinInsiderSell73,333$75.86$5,563,041.383,199,969View SEC Filing  
7/21/2017Gregg H AltonEVPSell40,000$74.00$2,960,000.00137,488View SEC Filing  
7/3/2017Gregg H AltonEVPSell5,000$71.06$355,300.00102,988View SEC Filing  
7/3/2017John C MartinInsiderSell73,333$71.00$5,206,643.003,199,969View SEC Filing  
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.7547,562View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.943,199,969View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00117,988View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.833,204,433View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00121,761View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.003,231,096View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00132,964View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.001,128,963View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.003,287,810View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.004,119,727View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.0064,122View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.001,170,963View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.004,119,727View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.0063,122View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.001,170,963View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.0063,122View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.004,119,727View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.001,170,963View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.0062,939View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00177,964View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.001,170,963View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.004,119,727View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.0063,122View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00147,090View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50110,523View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.003,948,066View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.0048,783View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.003,948,066View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.0048,783View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00127,936View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.001,029,108View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.0044,309View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00131,422View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.003,948,066View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00133,422View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00165,168View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.001,029,108View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00133,422View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.003,948,066View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.0048,783View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00135,422View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.0044,309View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.001,029,108View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.003,948,066View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00101,769View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.213,948,066View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00119,302View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.0049,832View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00130,694View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.504,429,387View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.0012,778View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.0049,832View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00119,302View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.0039,542View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.8428,562View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00132,694View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.504,429,387View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.0039,542View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00119,302View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.9628,562View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.0084,484View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.504,257,235View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00216,418View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.0032,938View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.002,159,643View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00161,840View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.002,159,643View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.0046,938View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.744,057,121View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.002,159,643View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Gilead Sciences (NASDAQ GILD) News Headlines

Gilead: Wheres The Next Catalyst?Gilead: Where's The Next Catalyst? - May 18 at 3:07 PM
EU warns of possible birth defect link to GSKs HIV drugEU warns of possible birth defect link to GSK's HIV drug - May 18 at 3:07 PM
Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)Gilead Sciences (GILD) Presents at Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript) - May 17 at 5:31 AM
$5.15 Billion in Sales Expected for Gilead Sciences (GILD) This Quarter$5.15 Billion in Sales Expected for Gilead Sciences (GILD) This Quarter - May 17 at 1:56 AM
Gilead Sciences Stock: How Much Upside Do Analysts Expect?Gilead Sciences Stock: How Much Upside Do Analysts Expect? - May 16 at 3:15 PM
A Look at Gilead Sciences’ Competitive ScenarioA Look at Gilead Sciences’ Competitive Scenario - May 16 at 3:15 PM
Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018Gilead Sciences’ Product Performance: A Mixed Bag in Q1 2018 - May 16 at 3:15 PM
FDA OKs expanded use for Gileads TruvadaFDA OKs expanded use for Gilead's Truvada - May 16 at 5:00 AM
Gilead Sciences Says FDA Approves Once-daily Oral TruvadaGilead Sciences Says FDA Approves Once-daily Oral Truvada - May 16 at 5:00 AM
 Brokerages Expect Gilead Sciences (GILD) to Announce $1.52 EPS Brokerages Expect Gilead Sciences (GILD) to Announce $1.52 EPS - May 15 at 9:22 PM
BRIEF-Gileads Kite Announces New Facilities, Expands Collaboration With National Cancer InstituteBRIEF-Gilead's Kite Announces New Facilities, Expands Collaboration With National Cancer Institute - May 15 at 3:01 PM
Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell ...Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell ... - May 15 at 3:01 PM
Kite Pharma continues buildout for cell therapy manufactureKite Pharma continues buildout for cell therapy manufacture - May 15 at 3:01 PM
Gilead Sciences (GILD) Says FDA Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 ...Gilead Sciences (GILD) Says FDA Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 ... - May 15 at 3:01 PM
Gilead Sciences: Resist Sentiment, Stop Speculating And InvestGilead Sciences: Resist Sentiment, Stop Speculating And Invest - May 15 at 3:01 PM
Why Trump’s drug-price pitch makes no senseWhy Trump’s drug-price pitch makes no sense - May 14 at 3:09 PM
Form 4 GILEAD SCIENCES INC For: May 09 Filed by: Whitley Richard JamesForm 4 GILEAD SCIENCES INC For: May 09 Filed by: Whitley Richard James - May 12 at 3:04 PM
Form 3 GILEAD SCIENCES INC For: May 09 Filed by: MANWANI HARISHForm 3 GILEAD SCIENCES INC For: May 09 Filed by: MANWANI HARISH - May 12 at 3:04 PM
You should know the cost of a drug or procedure before it...You should know the cost of a drug or procedure before it... - May 12 at 7:09 AM
Final Trade: IBB, GILD & moreFinal Trade: IBB, GILD & more - May 12 at 7:09 AM
Gilead May Rebound By 12% Short TermGilead May Rebound By 12% Short Term - May 10 at 3:09 PM
Harish Manwani Joins Gilead Sciences’ Board of DirectorsHarish Manwani Joins Gilead Sciences’ Board of Directors - May 10 at 5:01 AM
Lipotoxicity And NASH: Gileads Actions Speak Louder Than WordsLipotoxicity And NASH: Gilead's Actions Speak Louder Than Words - May 9 at 3:12 PM
What Investors Should Know About Gilead Sciences Inc’s (NASDAQ:GILD) Financial StrengthWhat Investors Should Know About Gilead Sciences Inc’s (NASDAQ:GILD) Financial Strength - May 9 at 5:09 AM
Gilead Sciences (GILD) Director Sells $379,865.24 in StockGilead Sciences (GILD) Director Sells $379,865.24 in Stock - May 8 at 4:15 PM
Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16 - May 8 at 3:02 PM
UK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filingUK biotech firm Autolus joins CAR-T rush with Nasdaq IPO filing - May 8 at 5:15 AM
Gilead Sciences (GILD) Downgraded to Hold at Zacks Investment ResearchGilead Sciences (GILD) Downgraded to Hold at Zacks Investment Research - May 7 at 1:13 PM
Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space?Could Unknown Orgenesis (ORGS) Be The Next Double Or Triple In The Cell Therapy Space? - May 7 at 8:01 AM
Wall Street Recommendations for Exelixis in May 2018Wall Street Recommendations for Exelixis in May 2018 - May 7 at 8:01 AM
Gilead Sciences (GILD) Expected to Earn Q2 2018 Earnings of $1.40 Per ShareGilead Sciences (GILD) Expected to Earn Q2 2018 Earnings of $1.40 Per Share - May 7 at 2:11 AM
Q2 2018 Earnings Estimate for Gilead Sciences Issued By Leerink Swann (GILD)Q2 2018 Earnings Estimate for Gilead Sciences Issued By Leerink Swann (GILD) - May 7 at 2:11 AM
William Blair Analysts Cut Earnings Estimates for Gilead Sciences (GILD)William Blair Analysts Cut Earnings Estimates for Gilead Sciences (GILD) - May 7 at 2:11 AM
Gilead Sciences (GILD) Receives Consensus Rating of "Buy" from AnalystsGilead Sciences (GILD) Receives Consensus Rating of "Buy" from Analysts - May 6 at 11:38 AM
Notable Friday Option Activity: GILD, EXEL, RIGNotable Friday Option Activity: GILD, EXEL, RIG - May 5 at 5:07 AM
BidaskClub Downgrades Gilead Sciences (GILD) to Strong SellBidaskClub Downgrades Gilead Sciences (GILD) to Strong Sell - May 5 at 12:29 AM
Is Gilead Sciences Stock Finally a Bargain?Is Gilead Sciences Stock Finally a Bargain? - May 4 at 3:13 PM
Top Stock Reports for BP, Gilead, Enterprise Products & ColgateTop Stock Reports for BP, Gilead, Enterprise Products & Colgate - May 4 at 3:13 PM
Allergan Reports Growth in 1Q18 RevenuesAllergan Reports Growth in 1Q18 Revenues - May 4 at 3:13 PM
Gilead Sciences, Inc. Stock Will Recover… EventuallyGilead Sciences, Inc. Stock Will Recover… Eventually - May 4 at 5:15 AM
Gilead Earnings: Is There A Silver Lining Somewhere?Gilead Earnings: Is There A Silver Lining Somewhere? - May 4 at 5:15 AM
Gilead Sciences, Inc. Stock Will Recover… EventuallyGilead Sciences, Inc. Stock Will Recover… Eventually - May 4 at 1:51 AM
Gilead Sciences (GILD) Downgraded by ValuEngine to "Buy"Gilead Sciences (GILD) Downgraded by ValuEngine to "Buy" - May 3 at 5:12 PM
Gilead Sciences: The Sales Tell The StoryGilead Sciences: The Sales Tell The Story - May 3 at 3:11 PM
Did Gilead Sciences Make a Big Mistake?Did Gilead Sciences Make a Big Mistake? - May 3 at 3:11 PM
Gilead Sciences (GILD) Director Sells $3,609,500.00 in StockGilead Sciences (GILD) Director Sells $3,609,500.00 in Stock - May 3 at 1:36 PM
5 Reasons You Shouldnt Worry About Gilead Sciences Ugly Q1 Results5 Reasons You Shouldn't Worry About Gilead Sciences' Ugly Q1 Results - May 3 at 7:18 AM
Gilead and Snap slip while Apple and AmerisourceBergen jumpGilead and Snap slip while Apple and AmerisourceBergen jump - May 2 at 4:27 PM
Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCVGilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV - May 2 at 3:10 PM
Analysts Show More Caution Toward Gilead’s Mystical RecoveryAnalysts Show More Caution Toward Gilead’s Mystical Recovery - May 2 at 3:10 PM

SEC Filings

Gilead Sciences (NASDAQ:GILD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Gilead Sciences (NASDAQ:GILD) Income Statement, Balance Sheet and Cash Flow Statement


Gilead Sciences (NASDAQ GILD) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.